Safeguard Biosystems

Safeguard Biosystems, founded in 2006, is a specialized firm operating within the molecular diagnostics industry. The company focuses on the research, development, and manufacturing of advanced diagnostic platforms designed for high-precision pathogen detection. By leveraging proprietary molecular technology, the organization provides critical tools for clinical and regulatory applications, positioning itself as a key player in the global biotechnology sector with annual revenues of $29.6M.

The company maintains a robust operational footprint with laboratory facilities and offices spanning Northvale, New Jersey, London, UK, Freiberg, Germany, and Toronto, Canada. Safeguard Biosystems supports its complex R&D and manufacturing workflows with a workforce of 500-1,000 employees. Meet Safeguard Biosystems's team to gain insights into the leadership and technical expertise driving their diagnostic innovations. Their organizational structure facilitates cross-border collaboration, ensuring that clinical and regulatory standards are met across diverse international markets.

Beyond human clinical diagnostics, the company’s technology has been adapted for agricultural applications, specifically detecting pathogens in infectious dairy cattle to ensure food safety. Safeguard Biosystems also operates a joint venture in the Philippines, Safeguard DNA Diagnostics Inc., which provides specialized testing for infectious diseases. The firm competes with established entities such as MicroGenDX, Streck, and New England Biolabs, continuously refining its diagnostic systems to maintain a competitive edge in the rapidly evolving molecular diagnostics market.